Results from patients with systemic lupus erythematosus (SLE) and from mice suffering from a lupus-like disease suggest that the IL-10 pathway is involved in pathogenesis, and that this cytokine could represent a target for managing SLE development. In this study, we constructed JC virus-like particles (VLP) expressing IL-10-specific short hairpin RNAs (shRNAs) that efficiently silenced IL-10 gene expression. In mice, a single injection of this preparation dramatically reduced serum levels of ILIO. We tested the preventive effect of this vector expressing anti-IL-10 shRNAs in female (NZBxNZW) F, mice. Weekly intraperitoneal injections decreased the incidence and severity of proteinuria, and prolonged lifespan, with reduced IL-10 production. Our data demonstrate that the IL-10 pathway plays a chief role in lupus pathogenesis. It indicates that JC virus-like particles represent a potent vector for delivering interfering RNA in vivo. They suggest that RNA interference targeting IL-10 is an effective strategy to silence the IL-10 pathway, and possesses a therapeutic potential that could be useful in the management of SLE and, possibly, other immune-mediated disorders.
DengYTsaoBP. Genetic susceptibility to systemic lupus erythematosus in the genomic era. Nat Rev Rheumatol2010; 6:683–92.
2.
ZoualiM. Epigenetics in lupus. Ann NY Acad Sci2011; 1217:154–165.
3.
TheofilopoulosANDixonFJ. Murine models of systemic lupus erythematosus. Adv Immunol1985; 37:269–390.
4.
HikadaMZoualiM. Multistoried roles for B lymphocytes in autoimmunity. Nat Immunol2010; 11:1065–8.
5.
RahmanAIsenbergDA. Systemic lupus erythematosus. N Engl J Med2008; 358:929–39.
6.
ZoualiMMageedRA. Cellular interactions and signalling defects in lupus (1). Lupus2008; 17:236–40.
7.
SaraivaMO'GarraA. The regulation of IL-10 production by immune cells. Nat Rev Immunol2010; 10:170–181.
8.
AletahaDLandeweRKaronitschT. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Ann Rheum Dis2008; 67:1360–4.
9.
FedorakRNGanglAElsonCO. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology2000; 119:1473–82.
RonnelidJTejdeAMathssonLNilsson-EkdahlKNilssonB. Immune complexes from SLE sera induce ILIO production from normal peripheral blood mononuclear cells by an FcgammaRII dependent mechanism: Implications for a possible vicious cycle maintaining B cell hyperactivity in SLE. Ann Rheum Dis2003; 62:37–42.
12.
CsiszarANagyGGergelyPPozsonyiTPocsikE. Increased interferon-gamma (IFN-gamma), IL-10 and decreased IL-4 mRNA expression in peripheral blood mononuclear cells (PBMC) from patients with systemic lupus erythematosus (SLE). Clin Exp Immunol2000; 122:464–70.
13.
UhmWSNaKSongGWJungSSLeeTParkMHYooDH. Cytokine balance in kidney tissue from lupus nephritis patients. Rheumatology (Oxford)2003; 42:935–8.
14.
EskdaleJWordsworthPBowmanSFieldMGallagherG. Association between polymorphisms at the human IL-10 locus and systemic lupus erythematosus. Tissue Antigens1997; 49:635–9.
15.
LlorenteLRichaud-PatinYGarcia-PadillaC. Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum2000; 43:1790–800.
16.
QiZMWangJSunZRMaFMZhangQRHiroseSJiangY. Polymorphism of the mouse gene for the interleukin 10 receptor alpha chain (I110ra) and its association with the autoimmune phenotype. Immunogenetics2005; 57:697–702.
17.
IshidaHMuchamuelTSakaguchiSAndradeSMenonSHowardM. Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice. J Exp Med1994; 179:305–10.
18.
DavidsonBLMcCrayPBJr. Current prospects for RNA interference-based therapies. Nat Rev Genet2011; 12:329–40.
19.
FrisqueRJBreamGLCannellaMT. Human Polyomavirus JC virus genome. J Virol1984; 51:458–69.
20.
TrowbridgePWFrisqueRJ. Analysis of G418-selected Rat2 cells containing prototype, variant, mutant, and chimeric JC virus and SV40 genomes. Virology1993; 196:458–74.
21.
GoldmannCPetryHFryeS. Molecular cloning and expression of major structural protein VP1 of the human Polyomavirus JC virus: Formation of virus-like particles useful for immunological and therapeutic studies. J Virol1999; 73:4465–9.
22.
ChenLSWangMOuWC. Efficient gene transfer using the human JC virus-like particle that inhibits human colon adenocarcinoma growth in a nude mouse model. Gene Ther2010; 17:1033–41.
23.
AbbingABlaschkeUKGreinS. Efficient intracellular delivery of a protein and a low molecular weight substance via recombinant polyomavirus-like particles. J Biol Chem2004; 279:27410–21.
24.
WangMTsouTHChenLSOuWCChenPLChangCFFungCYChangD. Inhibition of simian virus 40 large tumor antigen expression in human fetal glial cells by an antisense oligodeoxynucleotide delivered by the JC virus-like particle. Hum Gene Ther2004; 15:1077–90.
25.
ChenPLWangMOuWCLiiCKChenLSChangD. Disulfide bonds stabilize JC virus capsid-like structure by protecting calcium ions from chelation. FEBS Lett2001; 500:109–13.
26.
ChangJT. An economic and efficient method of RNAi vector constructions. Anal Biochem2004; 334:199–200.
27.
OuWCWangMFungCYTsaiRTChaoPCHseuTHChangD. The major capsid protein, VP1, of human JC virus expressed in Escherichia coli is able to self-assemble into a capsid-like particle and deliver exogenous DNA into human kidney cells. J Gen Virol1999; 80(Pt l):39–46.
28.
ChouMIHsiehYFWangMChangJTChangDZoualiMTsayGJ. In vitro and in vivo targeted delivery of IL-10 interfering RNA by JC virus-like particles. J Biomed Sci2010; 17:51.
29.
GerardCBruynsCMarchantAAbramowiczDVandenabeelePDelvauxAFiersWGoldmanMVeluT. Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia. J Exp Med1993; 177:547–50.
30.
ChangCFWangMOuWCChenPLShenCHLinPYFangCYChangD. Human JC virus-like particles as a gene delivery vector. Expert Opin Biol Ther2011; 11:1169–75.
31.
LlorenteLRichaud-PatinYWijdenesJ. Spontaneous production of interleukin-10 by B lymphocytes and monocytes in systemic lupus erythematosus. Eur Cytokine Netw1993; 4:421–7.
32.
ChunHYChungJWKimHAYunJMJeonJYYeYMKimSHParkHSSuhCH. Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus. J Clin Immunol2007; 27:461–6.
33.
CuiHDQiZMYangLLQiLZhangNZhangXLDuSYJiangY. Interleukin-10 receptor expression and signalling were down-regulated in CD4 T cells of lupus nephritis patients. Clin Exp Immunol2011; 165:163–71.
34.
ZhaoMTangJGaoFWuXLiangYYinHLuQ. Hypomethylation of IL10 and IL13 promoters in CD4+ T cells of patients with systemic lupus erythematosus. J Biomed Biotechnol2010; 2010:931018.
35.
MocellinSPanelliMCWangENagorsenDMarincolaFM. The dual role of IL-10. Trends Immunol2003; 24:36–43.
ViauMZoualiM. Effect of the B cell superantigen protein A from S. aureus on the early lupus disease of (NZBxNZW) F1 mice. Mol Immunol2005; 42:849–55.
38.
RamanujamMWangXHuangW. Similarities and differences between selective and nonselective BAFF blockade in murine SLE. J Clin Invest2006; 116:724–34.
39.
DingLShevachEM. IL-10 inhibits mitogen-induced T cell proliferation by selectively inhibiting macrophage costimulatory function. J Immunol1992; 148:3133–3139.
40.
McGeachyMJBak-JensenKSChenYTatoCMBlumenscheinWMcClanahanTCuaDJ. TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat Immunol2007; 8:1390–7.
41.
HuberSGaglianiNEspluguesE. Thl7 cells express interleukin-10 receptor and are controlled by Foxp3 and Foxp3+ regulatory CD4+ T cells in an interleukin-10-dependent manner. Immunity2011; 34:554–65.
